Compare Amgen, Inc. (AMGN) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while JPMorgan Nasdaq Equity Premium Income ETF trades at $60.08. The key difference: Amgen, Inc. pays a 2.77% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none. Which is the better fit depends on your goals.
| AMGN | JEPQ | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $388.16 | $61.46 |
52-Week Low | $271.18 | $53.77 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
JEPQ trades at $60.51, up 0.45% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on Nasdaq-100 exposure with a covered call strategy for income, as highlighted in recent financial media coverage. Recent dividends include $0.64 payable in July 2026, emphasizing its income-generation appeal.
The outlook for JEPQ hinges on its ability to balance Nasdaq-100 upside with income via options strategies. Key risks include capped upside during tech rallies and fee drag. Analyst sentiment is mixed, weighing high yield against potential underperformance versus the index in strong bull markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
